Evommune to License EVO570 Outside Greater China for $30 Million Upfront

The Tip Desk · November 8, 2026 · 3 min read

The clinical-stage biotech is adding an oral VAV1 degrader to expand into T- and B-cell-driven autoimmune diseases.

Evommune, Inc. (EVMN), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, entered an exclusive license agreement with Hinova Pharmaceuticals Inc. (688302) granting worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570, an oral VAV1-directed molecular glue degrader formerly known as HC118 and as HP570 in Greater China.

As consideration for the license, Evommune will pay Hinova $30 million upfront, consisting of $20 million in cash and $10 million in the form of pre-funded warrants to purchase Evommune common stock.

Hinova is eligible to receive up to approximately $1.1 billion in development, regulatory and commercial milestones, as well as tiered royalties on net sales outside Greater China.

The company said the addition is a strategic step that expands its pipeline into T- and B-cell-driven autoimmune diseases with a differentiated oral degrader that complements existing programs.

“Adding this development-stage program is a strategic step for Evommune, expanding our pipeline into T- and B-cell-driven autoimmune diseases with a differentiated oral degrader that complements our existing pipeline,” said Greg Moss, Chief Business and Legal Officer of Evommune.

VAV1 is a signaling protein that prominently drives T- and B-cell activation across a wide range of chronic inflammatory diseases. EVO570 is designed to selectively eliminate VAV1. Unlike JAK enzymes, which are broadly expressed across many tissues and organs, VAV1 is largely restricted to immune cells, a core rationale for its potential to offer a favorable safety and tolerability profile.

Investigational New Drug applications have been submitted in China and accepted in the United States, and a Phase 1 trial evaluating safety, pharmacokinetics and target engagement is on track to begin imminently. Evommune plans to initiate a Phase 2 trial in rheumatoid arthritis in 2027.

The license sits alongside two later-stage assets already in Phase 2. EVO756, an oral MRGPRX2 antagonist, has Phase 2b trials in chronic spontaneous urticaria and atopic dermatitis, with a migraine prophylaxis dose-ranging trial recently initiated. EVO301, a long-acting IL-18 binding protein, is moving toward a Phase 2b trial in atopic dermatitis after positive Phase 2a proof-of-concept data.

Evommune has described EVO756 as a potential first-line oral option after topical therapies and EVO301 as a preferred biologic for moderate-to-severe atopic dermatitis, with the two programs positioned to address different segments of the disease landscape.

The company reported a strong cash position expected to support operations through 2028, including a $125 million private placement in February 2026 that followed a $173 million IPO in November 2025.

EVO570 is an investigational drug candidate and has not yet been approved by any regulatory authority. The $30 million upfront package, split between cash and pre-funded warrants, is the consideration disclosed for the license.

Moss framed the oral degrader as complementary to the existing MRGPRX2 and IL-18 pipelines rather than a replacement for them. The company’s stated rationale is to broaden its autoimmune and inflammatory portfolio with a differentiated oral mechanism that targets T- and B-cell-driven disease.